Paul Hudson, CEO of Sanofi, told investors on Thursday, July 28th, that the company’s stock was the “least exposed” to competition from generics for the next decade. According to Hudson, the company’s only upcoming loss of exclusivity through 2030 is Aubagio. The company’s biggest seller, Dupixent, is still growing in sales and a generic is nowhere in sight in the 2020’s.
According to Fraiser Kansteiner, “Even still, “we know that it’s only really starting at this point,” Hudson said of Dupixent’s future trajectory. In fact, the company recently upgraded its peak sales target for Dupixent from 10 billion euros to more than 13 billion euros (about $14.44 billion), noting readouts in chronic obstructive pulmonary disease next year could garner even greater sales potential.”
To read more, click here.
(Source: Fierce Pharma, July 28th, 2022)